Home > Insider Trading > Filing (0001209191-19-050412)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1496323	Igm Biosciences Inc.	IGMS	Pharmaceutical Preparations (2834)	770349194

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1786442	Teng Christina Topsoe	C/O Igm Biosciences, Inc. 325 E. Middlefield Road Mountain View CA 94043		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-09-18	34,375	$16.00	34,375	No	4	P	Direct
Common Stock	Acquisiton	2019-09-18	1,250,000	$16.00	1,250,000	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2019-09-20	9,039,453	$0.00	10,289,453	No	4	C	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2019-09-20	9,039,453	$0.00	9,039,453	$0.00
Non-Voting Common Stock	Series C Preferred Stock	Disposition	2019-09-20	2,269,838	$0.00	2,269,838	$0.00
Common Stock	Non-Voting Common Stock	Acquisiton	2019-09-20	2,269,838	$0.00	2,269,838	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	C	Indirect
0	No	4	C	Indirect
2,269,838	No	4	C	Indirect

Footnotes

All shares are held directly by Haldor Topsoe Holding A/S (HTH). Mr. Jakob Haldor Topsoe, Ms. Christina Teng Topsoe, Mr. Martin Topsoe and Mr. Emil Oigaard, members of the board of directors of HTH, may be deemed to share voting and investment power with respect to the shares reported herein and disclaim beneficial ownership of such shares, except to the extent of his or her pecuniary interest therein, if any. Mr. Jakob Haldor Topsoe and Ms. Christina Teng Topsoe are members of the Issuer's board of directors.
The Series B Preferred Stock automatically converted into shares of Common Stock on a 1-for-1 basis immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
The Series C Preferred Stock automatically converted into shares of Non-Voting Common Stock on a 1-for-1 basis, pursuant to an election made by the Reporting Person, immediately prior to the closing of the Issuer's initial public offering, and had no expiration date. Each share of Non-Voting Common Stock is convertible at any time at the option of the Reporting Person into one share of Common Stock (subject to a 4.99% beneficial ownership limitation that may be increased or decreased by the Reporting Person) and has no expiration date.